Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

3.900 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	3.900
Bid (Size)	3.670 (300)
Ask (Size)	4.060 (3,200)
Prev. Close	3.900
Today's Range	3.900 - 3.900
52wk Range	1.670 - 6.600
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Q1 Earnings Call Highlights ↗

May 12, 2026

SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider...

Via MarketBeat

Performance

YTD	+3.4%	+3.4%
1 Month	+13.4%	+13.4%
3 Month	+3.2%	+3.2%
6 Month	+6.8%	+6.8%
1 Year	+122.2%	+122.2%

More News

SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage ↗

May 12, 2026

Via Chartmill

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 12, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

May 05, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

April 29, 2026

From Emergent BioSolutions

Via GlobeNewswire

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

April 22, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

April 15, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 19, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

March 10, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

March 09, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Participate in Upcoming Investor Conferences

March 02, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Participate in Upcoming Investor Conferences

February 04, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

January 07, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

December 18, 2025

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

December 17, 2025

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

December 08, 2025

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

November 13, 2025

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

November 04, 2025

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB BIO to Participate in Upcoming Investor Conferences

November 04, 2025

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 30, 2025

Via Benzinga

Frequently Asked Questions

Is SAB Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, SAB Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does SAB Biotherapeutics, Inc. - Common Stock trade on?

SAB Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for SAB Biotherapeutics, Inc. - Common Stock?

The ticker symbol for SAB Biotherapeutics, Inc. - Common Stock is SABS on the Nasdaq Stock Market

What is the current price of SAB Biotherapeutics, Inc. - Common Stock?

The current price of SAB Biotherapeutics, Inc. - Common Stock is 3.900

When was SAB Biotherapeutics, Inc. - Common Stock last traded?

The last trade of SAB Biotherapeutics, Inc. - Common Stock was at 06/29/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.